$4.87
0.09[1.88%]
At close: Apr 24
$4.87
0[0.00%]
PreMarket: 7:22PM EDT
ADC Therapeutics
(NYSE:ADCT)Latest News for ADC Therapeutics Stock (NYSE:ADCT)
ADC Therapeutics Stock (NYSE: ADCT)
Categories: All
Monday, April 15, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
- ADC Therapeutics shares are trading higher. The company announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA in combination with glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.Benzinga Newsdesk - Apr 4, 2024, 10:50AM
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin LymphomaBenzinga Newsdesk - Apr 4, 2024, 7:05AM
Thursday, March 28, 2024
- ADC Therapeutics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $11.Benzinga Newsdesk - Mar 28, 2024, 11:32AM
- Guggenheim Initiates Coverage On ADC Therapeutics with Buy Rating, Announces Price Target of $11Benzinga Newsdesk - Mar 28, 2024, 6:45AM
Thursday, March 14, 2024
Wednesday, March 13, 2024
- Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On WednesdayAvi Kapoor - Mar 13, 2024, 10:22AM
- ADC Therapeutics' 2023 Cash And Cash Equivalents Of $278.6M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025Benzinga Newsdesk - Mar 13, 2024, 7:04AM
- ADC Therapeutics Q4 Adjusted EPS $(0.97) May Not Be Comparable To $(0.50) Estimate, Sales $16.79M Beat $15.33M EstimateBenzinga Newsdesk - Mar 13, 2024, 7:02AM
- Earnings Scheduled For March 13, 2024Benzinga Insights - Mar 13, 2024, 6:15AM
Tuesday, March 12, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
Monday, February 26, 2024
- ADC Therapeutics shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $6 to $8Benzinga Newsdesk - Feb 26, 2024, 11:47AM
- RBC Capital Maintains Outperform on ADC Therapeutics, Raises Price Target to $8Benzinga Newsdesk - Feb 26, 2024, 10:21AM
Tuesday, February 20, 2024
Thursday, January 04, 2024
Monday, November 20, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
Tuesday, November 07, 2023
- ADC Therapeutics Sees Continued Decrease In Total Operating Expenses In FY23 And FY24 As Compared to FY22; Expected Cash Runway Into Middle of 2025Benzinga Newsdesk - Nov 7, 2023, 7:17AM
- ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsBenzinga Newsdesk - Nov 7, 2023, 7:16AM
- ADC Therapeutics Q3 Adj. EPS $(0.41) Beats $(0.63) Estimate, Sales $14.49M Miss $15.99M EstimateBenzinga Newsdesk - Nov 7, 2023, 7:13AM
- Earnings Scheduled For November 7, 2023Benzinga Insights - Nov 7, 2023, 6:34AM
Monday, November 06, 2023
Thursday, September 21, 2023
Tuesday, September 19, 2023
Tuesday, September 12, 2023
Monday, September 11, 2023
Wednesday, September 06, 2023
Tuesday, September 05, 2023
Thursday, August 31, 2023
Monday, August 28, 2023
Thursday, August 10, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
- ADC Therapeutics Sees FY23 Net Product Sales Growth Of Double-Digit Percentage Year-Over-YearBenzinga Newsdesk - Aug 8, 2023, 7:08AM
- ADC Therapeutics Q2 Adj EPS $(0.37) Beats $(0.44) Estimate, Sales $19.28M Miss $34.77M EstimateBenzinga Newsdesk - Aug 8, 2023, 7:04AM
- Earnings Scheduled For August 8, 2023Benzinga Insights - Aug 8, 2023, 4:48AM